Cytoreductive nephrectomy offers survival benefit in metastatic kidney cancer

The results of a trial looking at immunotherapy treatment with and without cytoreductive nephrectomy were presented at the 20th annual meeting of the Society of Urologic Oncology in Washington this week. The study included 391 patients diagnosed with metastatic renal cell carcinoma (RCC) between 2015 and 2016 from the National Cancer Data Base (NCDB). Of […]

read more

IKCS 2019: Immune related adverse events

Dr Mehmet Asim Bilen of Emory University School of Medicine in Atlanta, USA led a session at the International Kidney Cancer Symposium (IKCS) last month on the diagnosis and management of immune-related toxicity. Immune-related adverse events occur in some patients who are taking immune checkpoint inhibitors for the treatment of advanced renal cell carcinoma (RCC). […]

read more

Effectiveness of targeted therapy after immunotherapy in metastatic kidney cancer patients

In this retrospective international study, the effectiveness of targeted therapy following discontinuation of immunotherapy for patients with metastatic renal cell carcinoma (RCC) in the real world was investigated. There were 314 patients in the study; 276 (87.9%) were treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors (VEGFR-TKIs), such as sunitinib, axitinib and cabozantinib, […]

read more

New first-line immunotherapy plus TKI combinations for metastatic kidney cancer

Approval of axitinib plus pembrolizumab and axitinib plus avelumab in the first-line treatment of metastatic renal cell carcinoma (RCC) by both the Food and Drug Administration (FDA) in America and the European Commission represent milestone events for the treatment of metastatic RCC in 2019. Approval of the avelumab plus axitinib combination was based on the […]

read more

Pilot study of radiation therapy plus pembrolizumab for kidney cancer

A recent publication in the American Journal of Clinical Oncology this month reports on part of an exploratory study to look at the effect of radiotherapy alone or in combination with pembrolizumab on the immune system, and to determine the efficacy of this treatment in patients with solid tumours. This is the first study to […]

read more

Treatment of favourable-risk metastatic kidney cancer

The treatment of patients with intermediate- and poor-risk metastatic renal cell carcinoma (RCC) has been dramatically changed with the introduction of immune checkpoint inhibitors (immunotherapy) as a first-line of treatment after surgery. However, it is less clear whether immunotherapy benefits patients with favourable-risk disease in the same way. A debate between experts at the International […]

read more

Real world use of pazopanib after immunotherapy for advanced kidney cancer

A study published in Clinical Genitourinary Cancer last month describes the real world clinical outcomes of treating advanced renal cell carcinoma (RCC) patients with pazopanib after they had already been treated with immunotherapy. A total of 258 patients were enrolled in the study and had been treated with immunotherapy before pazopanib as follows: nivolumab (68%), […]

read more

Deciding on the ideal first-line treatment for rare and advanced kidney cancer

Currently, doctors are unsure which is the best first-line treatment for patients with rare and advanced kidney cancers. During a debate at the 18th International Kidney Cancer Symposium (IKCS), 5 doctors discussed their opinions. During the debate, the use of immunotherapy versus targeted kinase inhibitors (TKI) for the first-line treatment of advanced non-clear cell renal […]

read more

Comparison of first-line immunotherapy combinations for advanced kidney cancer

In this paper, three clinical trials with immunotherapy combinations for the first-line treatment of clear renal cell carcinoma (RCC) are discussed. Dr  Robert Motzer from Memorial Sloan Kettering Cancer Center in New York compared the findings from the three trials at the Annual Chemotherapy Foundation Symposium (CFS) in New York last week. All three phase […]

read more

The effect of antibiotic use on outcomes with kidney cancer drug treatments

A recent study has looked at the use of antibiotics with systemic drug treatments for renal cell carcinoma (RCC). The study investigated patients taking immune checkpoint inhibitors (146 patients), interferon-α (510 patients), mTOR inhibitors (660 patients) and VEGF targeted therapies (2,974 patients). The latter three groups were on phase II/III clinical trials, while the immunotherapy […]

read more
Showing 1 to 10 of 172 results
  TOP